Skip to content
PepFitCoach™
← Peptide library

Metabolic

Tirzepatide

Approved medicineHuman clinical evidence

FDA-approved (type 2 diabetes; chronic weight management)

In simple words: A once-a-week prescription injection that copies two gut hormones (GIP and GLP-1) to lower appetite and blood sugar.

How it works

It helps the pancreas release insulin when blood sugar is high, slows stomach emptying and signals fullness to the brain.

Targets: GIP receptor, GLP-1 receptor · Class: Dual GIP / GLP-1 receptor agonist

Uses, latest studies & pairings

Typically used for

  • Type 2 diabetes (Mounjaro).
  • Chronic weight management, and moderate-to-severe obstructive sleep apnea with obesity (Zepbound).
  • Also studied for heart failure with obesity, fatty liver and kidney disease.

Commonly paired with

  • Strength training and enough protein (about 1.2–1.6 g per kg of body weight a day, unless your doctor says otherwise) to protect muscle while losing weight.
  • Not combined with other GLP-1 medicines: they work on the same receptors, so stacking adds side effects, not safety.
  • Fiber, water and electrolytes to ease constipation and nausea.
  • In diabetes, doctors may combine it with metformin, but insulin or sulfonylureas raise the risk of low blood sugar and often need lowering.

Latest studies & news

  1. 2026

    Head-to-head (REDEFINE 4): tirzepatide averaged 25.5% weight loss versus 23.0% with CagriSema.

  2. 2025

    SURMOUNT-5: tirzepatide beat semaglutide head-to-head, about 20% versus 14% average weight loss at 72 weeks.

  3. 2025

    SURPASS-CVOT: in people with type 2 diabetes and heart disease, it was at least as good as dulaglutide (Trulicity) at preventing heart attacks, strokes and heart deaths.

What the research shows

Human clinical evidence

Human
  • SURMOUNT-1 (72 weeks, adults with obesity): average weight loss of about 15–21% depending on dose, versus about 3% with placebo (Jastreboff 2022).
  • Approved in the US for type 2 diabetes (Mounjaro) and for chronic weight management and obstructive sleep apnea with obesity (Zepbound).

Animal and lab results suggest what might happen; they don't prove an effect in people.

Safety & what to watch

  • Common: nausea, diarrhea, vomiting, constipation, especially after dose increases.
  • Boxed warning: thyroid C-cell tumors in rodents; not for people with a personal or family history of MTC or MEN 2.
  • Label warnings include pancreatitis, gallbladder disease, low blood sugar with insulin or sulfonylureas, and dehydration-related kidney problems.

Amounts

Prescription only. Your prescriber follows the label's step-up schedule and decides every dose change.

📦 My peptide supply kit

The supplies I use, in one Amazon list. Only use them for medicines your clinician prescribes. Never share or reuse needles, and put used ones in a sharps container.

See my peptide supply kit list on Amazon ↗

Studies & references

  1. Jastreboff et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022PMID 35658024
  2. FDA prescribing information (DailyMed)
  3. All PubMed studies: tirzepatide

Draft profile pending editorial review. Educational only, not medical advice. Never start, stop or change a medicine without your prescriber.